Microdermics is a Vancouver, Canada–based developer of an innovative microneedle platform for delivery of vaccines and biologics. Its microneedles are less than 1 mm long and are designed to deliver medicine into the upper dermis, avoiding blood vessels and nerve tissue. The approach aims to be less painful and to produce more efficient and improved biological responses. The technology is built on research at the University of British Columbia. Led by Grant Campany (president and CEO), the company plans to use new funding for scale-up and clinical validation studies to support current and future corporate collaborations. The company recently closed a $1M financing round to advance these efforts.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2017